|
GB9727455D0
|
|
Formulation of nucleic acid formation
|
|
GB9727456D0
|
|
Conjugate compounds useful for non-viral gene therapy and methods for the production thereof
|
|
GB9726641D0
|
|
Pharmaceutical compositions for delvery of nucleic acid to cell nucleus
|
|
GB9721376D0
|
|
Methods and compositions for enhanced gene delivery
|
|
WO9728818A1
|
|
Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
|
|
GB9626992D0
|
|
Optimization of gene delivery and gene delivery systems
|
|
GB9626986D0
|
|
Pharmaceutical compositions for delivery of nucleic acid to cell nucleus
|
|
GB9626969D0
|
|
Conjugate compounds useful for non-viral gene therapy and methods for the production thereof
|
|
GB9626996D0
|
|
Formulation of nucleic acid compositions
|
|
GB9626092D0
|
|
Pharmaceutical compositions for delivery of nucleic acid to cell nucleus
|
|
GB9619597D0
|
|
Culture system
|
|
GB9617214D0
|
|
Vector
|
|
GB9614548D0
|
|
A delivery vehicle
|
|
CA2224146A1
|
|
Improved pharmaceutical compositions for gene therapy
|
|
ZA9604925B
|
|
Pharmaceutical compositions for gene therapy.
|
|
AU6011496A
|
|
Improved pharmaceutical compositions for gene therapy
|
|
GB9607819D0
|
|
Anti-hiv agents
|
|
GB9607239D0
|
|
A vector
|
|
GB9602777D0
|
|
Delivery vehicle
|
|
GB9602825D0
|
|
Method of plasmid dna production and purification
|
